Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Share on facebook
Share on twitter
Share on linkedin

September 26, 2012: Broad Infectious Disease Patent Issued in China for Plasma Gelsolin

BioAegis’ Patent Coverage Expands to Asia

Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria and this broad patent filing was recently granted in China. BioAegis is pursuing worldwide patent filings for infectious disease.